www.fdanews.com/articles/86585-aerovance-secures-60-million-in-financing
AEROVANCE SECURES $60 MILLION IN FINANCING
May 5, 2006
Aerovance Inc., a biopharmaceutical company with a portfolio of clinical-stage drugs targeting severe respiratory and inflammatory diseases, today announced it has secured $60 million in Series C financing.
Drug Newswire (http://www.drugnewswire.com/1834/)